Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials

Vilazodone is a new molecule approved for major depressive disorder (MDD). This report focuses on the efficacy and tolerability of vilazodone for MDD. MEDLINE, EMBASE, and Cochrane Library were searched. A total of 1,930 patients from four trials were included. A significant improvement in the Montg...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Ligen, Wang, Jingyi, Xu, Shenbin, Lu, Yunrong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135073/
https://www.ncbi.nlm.nih.gov/pubmed/27932864
http://dx.doi.org/10.2147/DDDT.S122085

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5135073/
https://www.ncbi.nlm.nih.gov/pubmed/27932864
http://dx.doi.org/10.2147/DDDT.S122085

Ejemplares similares